contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Gubra er en medicinalvirksomhed. Virksomhedens aktiviteter er fokuseret på de tidlige stadier af lægemiddeludvikling. De udfører hovedsageligt forskning og udvikling inden for stofskifte- og fibrotiske sygdomme.Virksomhedens produktportefølje omfatter flere brands og lægemidler, og aktiviteterne foregår på globalt plan med den største tilstedeværelse i Nordamerika og Norden. Hovedkontoret ligger i Hørsholm, Danmark.

Gubra

The key highlight of the quarter was the partnership agreement with AbbVie for the weight loss candidate GUBamy, featuring upfront, milestone, and royalty payments totaling USD 2.2 billion. During the quarter, Gubra announced a strategic shift in focus towards its D&amp;P division, with the aim of advancing more projects into clinical development and expanding its research scope to include Women&apos;s Health. Gubra reiterates its full-year 2025 guidance.
Financial highlights from Q1-2025
<img src="https://content.inderes.se/assets/74aeec1f-a16c-45cb-97ba-4c9a1a5bc40b?width=672&amp;height=354" alt="Gubra Key Highlights">
CRO:&#xa0;Revenue in the first quarter amounted to DKK 50.6 million. Compared to the corresponding quarter in 2024, revenue was down by 14% and down 8% compared to the average quarterly level in 2024.&#xa0;For Q1 2025, no special items were included resulting in EBIT reconciling for adjusted EBIT. EBIT was DKK 10.8 million in Q1 2025 with EBIT-margin of 21% compared to adjusted EBIT of DKK 22.6 million in Q1 2024 (reported DKK 21.5 million) and adjusted EBIT-margin for Q1 2024 at 39% (reported 37%).
D&amp;P: Revenue in the first quarter amounted to DKK 6.9 million compared to DKK 6.5 million in Q1 2024. Adjusted EBIT in the first quarter was DKK -54.2 million compared to DKK -26.6 million in Q1 2024. The decrease in EBIT was primarily due to increased costs for our most mature development programs GUBamy and UCN2 as we advance these programs through the development stages.&#xa0;With the closing of the AbbVie transaction occurring after Q1 2025 (closing occurred on 1 April 2025), the upfront payment of USD 350 million was not recognized in the accounts for Q1 2025.
Gubra keeps financial 2025 guidance:
<img src="https://content.inderes.se/assets/4dded162-1c67-485c-9e82-5e701ad683ca?width=603&amp;height=205" alt="Gubra 2025 Guidance">
Following the end of the quarter, regulatory authorities approved the partnership agreement with AbbVie regarding GUBamy, , and Gubra announced positive results from the MAD study on GUBamy.
Read full trading statement here: <a href="https://investors.gubra.dk/news-and-announcements/news-details/default.aspx?slug=trading-statement-q1-2025-a-landmark-deal-for-gubamy" target="_blank" rel="noopener">Gubra Q1 trading statement</a>
Sign up here for today&#x2019;s investor event with CEO Henrik Blou and CFO Kristian Borbos: <a href="https://www.inderes.dk/videos/gubra-praesentation-af-q1-2025" target="_blank" rel="noopener">Today&apos;s Gubra event</a>
Disclaimer: HC Andersen Capital is compensated by Gubra as part of a Digital IR subscription agreement. /Claus Thestrup, 9 May 2025 at 08:18 AM.

Gubra: Trading statement Q1-2025

Gubra

Privatlivspræferencer